D. Massey

发表

First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.

E. Bateman, R. Dahl, N. Zhong, 2010, Respiratory medicine.

LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

K. O'Byrne, T. Mok, E. Tan, 2015 .

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study

W. Poewe, O. Rascol, M. Mcdermott, 2009 .

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Evaluation of the efficacy and safety of tiotropium bromide (5 &mgr;g) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease

N. Zhong, Yan Tang, D. Massey, 2013, Chinese medical journal.

L. Sequist, K. O'Byrne, T. Mok, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

L. Sequist, S. Ou, T. Mok, 2015, The Lancet. Oncology.

Empagliflozin in Patients with Chronic Kidney Disease

M. Landray, A. Levin, C. Wanner, 2022, The New England journal of medicine.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

J. Canon, J. Vansteenkiste, P. Vuylsteke, 2015, Lung cancer.

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

E. Tolosa, W. Poewe, O. Rascol, 2010, The Lancet Neurology.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

L. Sequist, K. O'Byrne, T. Mok, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer

A. Marchetti, F. Cappuzzo, A. Santoro, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

L. Sequist, K. O'Byrne, T. Mok, 2017, The Patient - Patient-Centered Outcomes Research.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Y Huang, L. Sequist, K. O'Byrne, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3

K. Kiura, I. Okamoto, N. Yamamoto, 2015, Cancer science.

Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997–2001

D. Price, J. Ayres, M. Pearson, 2006, International journal of chronic obstructive pulmonary disease.

XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.

H. Rugo, H. Burris, P. Schmid, 2019, Journal of Clinical Oncology.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

W. Poewe, O. Rascol, A. Schapira, 2013, The Lancet Neurology.